Assessment of Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Using MRI and 18F FDG PET/CT
Objective: Neoadjuvant chemotherapy (NACT) has been the primary treatment method for patients with local advanced breast cancer. A pathological complete response (pCR) to therapy correlates with better overall disease prognosis. Magnetic resonance imaging (MRI) and positron emission tomography/compu...
Saved in:
| Main Authors: | Reem Yusuf AlBuainain, Fatema Yusuf Bunajem, Hussain Adnan Abdulla |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2025-01-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: | https://www.eurjbreasthealth.com/articles/assessment-of-tumor-response-to-neoadjuvant-chemotherapy-in-breast-cancer-using-mri-and-lesssupgreater18lesssupgreaterf-fdg-petct/doi/ejbh.galenos.2024.2024-8-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of [<sup>18</sup>F]FDG PET/CT Prior to and During Neoadjuvant Chemotherapy for Soft Tissue Sarcomas
by: Stijn J.C. van der Burg, et al.
Published: (2025-04-01) -
The Relationship between Pathological Features and 18F-FDG PET/CT that Changed the Surgeon's Decision as Neoadjuvant Therapy in Breast Cancer
by: Akay Edizsoy, et al.
Published: (2022-06-01) -
Evaluation of pre-treatment F-18 FDG PET/CT according to Mandard classification in locally advanced rectal cancer patients undergoing neoadjuvant chemoradiotherapy
by: Feray Aras, et al.
Published: (2025-08-01) -
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Key Points:
by: Maeve A. Hennessy, et al.
Published: (2025-06-01) -
FDG PET/CT AND PSMA PET/CT IN MUSCULOSKELETAL SOFT TISSUE SARCOMAS
by: Ellen Nogueira Lima, et al.
Published: (2025-05-01)